期刊
CHEMICAL COMMUNICATIONS
卷 58, 期 14, 页码 2383-2386出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/d1cc06525d
关键词
-
资金
- Mayo Clinic Foundation
- ARA grant
- National Institutes of Health [R01CA134514, R01CA130908, R01CA197178, R01CA249282]
In this study, a new ligand of cereblon (CRBN) E3 ubiquitin ligase, 3-aminophthalic acid, was identified and a phthalic acid-based O'PROTAC was developed for degradation of the ERG transcription factor. This phthalic acid-based O'PROTAC exhibited comparable efficacy in degrading ERG to pomalidomide-based ERG O'PROTACs. Moreover, phthalic acid, being more chemically stable and economical than classical immunomodulatory drugs (IMiDs), represents a new alternative as a ligand for the development of PROTACs, especially O'PROTACs.
In this study, we identified 3-aminophthalic acid as a new ligand of cereblon (CRBN) E3 ubiquitin ligase and developed a phthalic acid-based O'PROTAC for degradation of the ERG transcription factor. This phthalic acid-based O'PROTAC presented an efficacy in degrading ERG comparable to those displayed by pomalidomide-based ERG O'PROTACs. Moreover, phthalic acid-being more chemically stable and economical than classical immunomodulatory drugs (IMiDs)-represents, as a ligand, a new alternative for the development of PROTACs, especially O'PROTACs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据